University of Sheffield
Latest From University of Sheffield
Combining Editas’ CRISPR gene-editing technology with BlueRock’s pluripotent stem cell capabilities, the companies hope to leverage each other to create novel gene therapies for cancer, neurological, cardiovascular and autoimmune diseases.
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced February through March 2014.
One of the major challenges faced by a European medtech start-up community that is already arguably undersized has been a lack of infrastructure. A group of medical device executives are trying to address that problem through the launch of an incubator, InMedica, built upon a network of support services that is integrally connected to the incubator, in effect forming its own medical device cluster in the unlikely setting of Slovenia, a country of two million people in south central Europe.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.